Loading clinical trials...
Loading clinical trials...
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough
Conditions
Interventions
NOC-110
Placebo
Locations
107
United States
G & L Research, LLC
Foley, Alabama, United States
Medical Research of Arizona
Scottsdale, Arizona, United States
AMR Phoenix
Tempe, Arizona, United States
Little Rock Allergy & Asthma, P.A. Clinical Research Center
Little Rock, Arkansas, United States
So Cal Clinical Research
Huntington Beach, California, United States
Allergy and Asthma Associates of Southern California dba Southern California Research
Laguna Niguel, California, United States
Start Date
September 24, 2024
Primary Completion Date
April 10, 2026
Completion Date
April 10, 2026
Last Updated
February 17, 2026
NCT04471337
NCT04265781
NCT04454424
Lead Sponsor
Nocion Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions